There is a difference between treating particularly unresponsive cases of S. aureus with phage therapy and it becoming the frontline standard of care for all ba

There is a difference between treating particularly unresponsive cases of S. aureus with phage therapy and it becoming the frontline standard of care for all bacterial diseases. Additionally, Russia has done the investment in laboratory capacity in order to do phage therapy. Introducing it into the United States would require new equipment, space and staffing in order to facilitate more widespread culturing (as there are no "broad spectrum" phages), as well as the actual preparation of phage-based therapeutics.